Midatech Pharma Share Discussion Threads

[rathkum] 02/5/2018 15:10

Interesting. Takeover?

[gwatson56] 02/5/2018 14:53

MTP on Nasdaq up over 60% ...

[ih_433513] 28/2/2018 07:46

MTD119 - not even got IND status yet. They claim big news on nothing events like getting approval to conduct a Phase 1 trial! The only thing of any importance now is getting bioequivalence confirmed on MTD201. Of course that was supposed to have happened in late 2017 - now it’s H1 2019. Endless delays on top of the insulin drug failure.

[gary38] 28/2/2018 07:27

Midatech Pharma PLC Midatech gets Orphan Drug Designation for MTD119 07:06 : Wednesday 28 February 2018 

[ih_433513] 27/2/2018 17:43

Another new low. So much for this company having multiple shots at success. If 201 isn’t bioequivalent that could be it folks.

[jamtomorrow2] 22/2/2018 06:58

Another new low. Those peak sales forecasts for both MTD201 and the brain cancer drug look pure fantasy to me. Sandostatin is not patent protected anymore and it looks like three generics will be on the market before MTD201 is launched in 2020. The price by that time will be way lower than now - something that the forecasts haven’t taken into account. Also the brain cancer drug has such a limited market that I have no idea how they have arrived at their figures. Bearing in mind that DARA seems to be incapable of marketing its existing drugs it’s very hard to fathom how they will be capable of selling 10-15 times the current sales level.

Also what happens to the recently negotiated loan if MTD201 fails to achieve bioequivalence? We haven’t been told the terms and conditions attached to the loan but one would assume that it would be subject to meeting certain drug development goals and surely MTD201 bioequivalence is one of those goals. Would the loan then have to be repaid quickly leaving MTPH in desperate need of new cash just as the share price crashes further?

Continous delays and a plethora of unanswered questions surround this company.

[ih_433513] 14/2/2018 16:58

More delays on MTD-201. What is wrong with these people?

[gary38] 14/2/2018 09:57

That looks very impressive .

[gary38] 14/2/2018 09:56

Midatech Pharma PLC Trading UpdateSource: UK Regulatory (RNS & others)TIDMMTPHRNS Number : 8075EMidatech Pharma PLC14 February 201814 February 2018Midatech Pharma PLC("Midatech", "Company" or "Group")Trading updateMidatech (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products in oncology, today provides a trading update ahead of its full year results for the twelve months ended 31 December 2017.With a diversified strategy, multiple sources of revenue and an innovative R&D pipeline, Midatech has made good progress across the Group. Based on unaudited results, and in line with market expectations, reported total net revenues for the twelve months ended 31 December 2017 are expected to be at least GBP7.4m (2016: GBP6.9m), including US product sales of GBP6.7m (2016: GBP5.2m), an increase of 29% on the previous year (32% increase in USD). Whilst still subject to final audit approval, the US operation also reached break-even in H2 2017. The board continues to focus on managing costs and the group net cash balance as at 31 December 2017 was GBP13.2m (2016: GBP17.6m), also in line with market expectations.

[qackers] 12/2/2018 22:54

Looked like he had been trying some of his products.
Still factually encouraging I thought

[ih_433513] 12/2/2018 20:42

That TV guy who can telling whether someone is telling the truth or lying from facial and bodily movements/expressions would have a field day analysing Jim’s performance on the proactive video. That involuntary gulping - oh dear.

[edrifter] 12/2/2018 04:18

Excellent - thanks for posting that.

[riddlerone] 11/2/2018 14:14

Nice Update
hxxp://www.proactiveinvestors.co.uk/companies/stocktube/8717/critical-year-ahead-of-drug-development-for-midatech-pharma-8717.html

[jamtomorrow2] 16/1/2018 23:04

The share price is 45p for a reason. One failed trial, a loss making acquisition and two approvals to conduct a trial after 3 years as a public company. That’s all folks. But at least one shareholder seems happy.

[luffness] 16/1/2018 15:12

and on what planet do you think they will get approvals without trials ?

[jamtomorrow2] 16/1/2018 14:53

What we need are drug approvals not approvals to conduct trials. These last two ‘approvalsR17; are supposed to excite us? Personally I’m appalled it’s taken so long to get these two ‘approvalsR17;. 2019 read out of today’s trial - geez. What was the point of wasting money on buying loss making DARA when they aren’t going to have any of their own drugs to market through DARA for years. Management has lost focus completely. If MTD201 isn’t deemed to be bio-equivalent in 2018 I’m starting to think that the company may not survive. Personally I’d dump DARA and hopefully recover something for it. I suspect that DARA’s 2017 loss and continuing loss forecast for 2018 will be significant. So much for breakeven by late 2017.

[18bt] 16/1/2018 07:30

Another announcement. Niche market but some potential

[jamtomorrow2] 09/1/2018 23:02

MTD201 study approved!! Somewhat misleading headline! I was under the impression that it had been approved to commence ages ago. Nobody ever said the hold-up was due to not having EU approval. So the previously quoted reason for the hold-up of problems relating to gearing up to production levels at the Spanish lab was basically as misleading as the heading to today’s announcement. So when is this wretched trial actually going to start? It’s delay after delay after delay. No wonder the share price is so bombed out. Also why do we hear nothing about the success or otherwise of the compansionate UK program re childrens brain cancer? This had been going on for a couple of years now. If successful you’d have thought they’d be singing out the good news from the rooftops.

[jimbo123elf] 09/1/2018 09:45

Very interesting RNS today

Q-Octreotide (MTD201) is Midatech's treatment for carcinoid cancer and acromegaly built on its Q-SpheraTM sustained release platform technology. The somatostatin analogue treatment for carcinoid cancer and acromegaly is being developed as the first alternative version of the commercial leading product, Sandostatin® LAR (SLAR). During its pre-clinical programme, data suggested that Q-Octreotide has an equivalent profile to the Novartis SLAR and may offer some important advantages to clinicians and patients. Midatech believes that if these data are confirmed in the upcoming study Q-Octreotide could capture up to a 5% share of the market for SLAR, which is worth $2bn annually1.

That's a potential £74m a year uplift if confirmed.

[jamtomorrow2] 03/1/2018 12:02

There are 1.8m ADRs outstanding.

[luffness] 03/1/2018 11:35

Looks like Yahoo didnt update shares in issue after the last placing

[edrifter] 03/1/2018 11:29

Ok. So what would the shares outstanding figure on YahooUS refer to? Total shares converted to ADR's? It is also hard to see that the total ADR stock would have been rotated through 3 times. Possible I guess - but I have US ADR's, and with that level of demand I would have probably been getting phone calls, asking if I wanted to sell!

[jamtomorrow2] 03/1/2018 11:16

5.82m ADRs (yesterday’s Nasdaq volume) is about 3 times the total number of ADRs in existence. I checked.

[edrifter] 03/1/2018 02:43

Yahoo US quotes 48.72M outstanding shares - which I take to be the ADR's of which there is a float of 21.14M. UK 61.08M, with a float of 42.29M. US volume of 5,820,656 would represent 27% of the US float. 144k in the UK is paltry by comparison - which is in itself pretty interesting.